Product acquisition

Focus is well positioned financially and strategically to acquire tail–end brands or under–utilised prescription only products.

Company latest

News and press

April 2015

Focus successful in UK litigation against Novartis concerning Voleze® Rivastigmine Transdermal Patches

Through Focus’s financial strength and understanding of the divestment process from both sides, we are a Company with a history of making sure the acquisition process is both efficient and beneficial to the Company divesting the product. Focus prefers to acquire prescription only medicines, concentrating on the UK and Irish market.